Novo Nordisk A/S (NVO)

In our optimistic scenario for NVO, the stock could reach $179.79 over the next 12 months, representing a 299.9% gain from today's price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company ...

Novo Nordisk (NVO) stock in focus as the EMA recommends oral Wegovy for Europe, making it the continent's first oral weight-loss drug to clear regulatory review.

May 20, 2026, 5:49 AM ETNovo Nordisk A/S (NVO) Stock, NONOF Stock, NOVO:CA Stock, NVON:CA StockLLY, LLY:CA, ZLLY:CA ... I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings.

Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.

Novo Nordisk’s first-quarter results drew an initial warm reception, but enthusiasm faded as investors digested a significant one-off windfall, broad-based sales declines in reported currency and the distortion of constant-currency framing.